Afatinib Expanded Access Program

• Conditions: Carcinoma, Non-Small-Cell Lung

• Registration Number: NCT01649284
• Lead Sponsor: Boehringer Ingelheim

Brief Summary

This is an open-label, multi-center, single-arm trial, designed to provide early access to afatinib and to provide additional information on the safety and efficacy of afatinib in advanced NSCLC patients who harbor an EGFR mutation.

Detailed Description

Not available

Study Timeline

• Study Start: 2012-07
• Study First Submitted: 2012-07-23
• Study First Submitted QC: 2012-07-23
• Study First Posted: 2012-07-25
• Primary Completion: 2014-03
• Study Completion: 2014-03
• Status Verified: 2015-03
• Last Update Submitted: 2016-11-29
• Last Update Posted: 2016-11-30

Recruitment & Eligibility

• Status: APPROVED_FOR_MARKETING
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: EXPANDED_ACCESS
• Study Design: Not specified

Trial Locations

Locations (66)

1200.45.004 Boehringer Ingelheim Investigational Site; 🇺🇸 Mobile, Alabama, United States

1200.45.116 Boehringer Ingelheim Investigational Site; 🇺🇸 Goodyear, Arizona, United States

1200.45.057 Boehringer Ingelheim Investigational Site; 🇺🇸 Hot Springs, Arkansas, United States

1200.45.078 Boehringer Ingelheim Investigational Site; 🇺🇸 Anaheim, California, United States

1200.45.114 Boehringer Ingelheim Investigational Site; 🇺🇸 Burbank, California, United States

1200.45.123 Boehringer Ingelheim Investigational Site; 🇺🇸 Glendale, California, United States

1200.45.115 Boehringer Ingelheim Investigational Site; 🇺🇸 Lakewood, California, United States

1200.45.117 Boehringer Ingelheim Investigational Site; 🇺🇸 Long Beach, California, United States

1200.45.102 Boehringer Ingelheim Investigational Site; 🇺🇸 Monterey, California, United States

1200.45.091 Boehringer Ingelheim Investigational Site; 🇺🇸 Pleasant Hill, California, United States

Scroll for more (56 remaining)